United States:
Podcast: DOJ's New Guidance On Evaluating Compliance Programs: What You Need To Know
20 September 2019
Akin Gump Strauss Hauer & Feld LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Subscribe to OnAir with Akin Gump via iTunes, SoundCloud YouTube, Spotify and Google Play.
In this episode, Akin Gump health care and life sciences counsel
Taylor Jones and Matt Wetzel discuss the Justice
Department's recent guidance on evaluation of corporate
compliance programs.
Among the topics covered:
- Incorporating the guidance into risk
assessment.
- Its impact on the health care
sector.
- What it may reveal about DOJ
compliance strategy.
- Top takeaways.
For more information on Akin Gump's health care and life
sciences work, please visit
the health care and life sciences page on
akingump.com.
Download PDF
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Corporate/Commercial Law from United States
Corporate Transparency Act Update
Shulman Rogers
With the arrival of spring and the first set of Corporate Transparency Act (CTA) filing deadlines behind us, it is a good time for an update on lessons learned from the initial filings.
Compliance Isn't The Only 'AI Washing' Risk
Bracewell
Companies are rapidly adopting artificial intelligence technologies, and both regulators and private plaintiffs have set their sights on "AI washing," where businesses tout AI capabilities that do not exist.